Navigation Links
Sangamo BioSciences Announces Presentation of Phase 1 Data of ZFP Therapeutic at International Society for Cellular Therapy (ISCT) Meeting
Date:5/19/2008

"http://www.sangamo.com" target="_new">http://www.sangamo.com.

This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-509, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the initiation and completion of stages of the SB- 509 clinical trials, whether the SB-509 clinical trials will validate and support tolerability and efficacy of SB-509, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Sangamo BioSciences Nominates Thomas G. Wiggans to Its Board of Directors
2. Sangamo BioSciences Announces First Quarter Conference Call and Webcast
3. Sangamo BioSciences Announces License Agreement For the Use of ZFP Technology For Generation of Transgenic Animals
4. Sangamo BioSciences to Present at the Cowen and Company 28th Annual Health Care Conference
5. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
6. Dow AgroSciences, Sangamo BioSciences Announce the Achievement of Key Milestone in Plant Agriculture Collaboration
7. Sangamo BioSciences to Present at the BIO CEO & Investor Conference
8. Sangamo BioSciences Announces Fourth Quarter and Year-End 2007 Conference Call and Webcast
9. Sangamo BioSciences to Webcast Presentations at Investor and Analyst Briefing
10. Sangamo BioSciences to Present at the BMO Capital Markets Health Care Conference
11. Sangamo BioSciences to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... and HONG KONG , Oct. ... disease therapeutics enterprise, announced today that rare disease expert ... as vice president, research. Dr. McKew brings more than ... leadership positions at the National Institutes of Health, Wyeth ... by Wyeth). Dr. McKew will lead aTyr,s efforts to expand ...
(Date:10/20/2014)... , Oct. 20, 2014 Mapp ... experimental ZMapp™ antibody therapeutic to fight the Ebola ... difficult and time-consuming the production of pharmaceuticals can ... research publisher said that while some may be ... this compound, those with industry knowledge are well ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... 2014 , A major pan-European ... the delivery of care has revealed changing trends in ... in the provision of healthcare services across the continent. ... United European Gastroenterology (UEG), have been announced today and ... of the burden of GI disorders across ...
Breaking Biology Technology:aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 2aTyr Pharma Appoints John C. McKew, Ph.D., as Vice President, Research 3Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5
... 2008 at this year,s liver ... 4, SAN FRANCISCO, Oct. 27 Nonalcoholic steatohepatitis,(NASH) ... approved,medical therapy for this chronic progressive liver disease. Researchers,tested ... program. To do so, 31 overweight or obese patients ...
... Oct. 27 Carna Biosciences, Inc. ("Carna"),announced on ... Agreement with,Shanghai Universal Biotech Company ("SUBC"). Under the ... distributor of Carna,s Protein,Kinases within China., With ... in,the life sciences, major biopharmaceutical companies have now ...
... BioAtom Inc. (private) announced,today that it will present ... 28, 2008 at 2:30 PM PDT (5:30 PM EDT) ... Myron Karasik, M.B.A., C.M.C., Director of Finance, will ... Costa Mesa, CA, dedicated,to development and commercialization of Neutron ...
Cached Biology Technology:Intensive Lifestyle Intervention Program for Overweight or Obese Patients with Nonalcoholic Steatohepatitis Reduces Weight and Improves Overall Liver Health 2Carna Biosciences Signs Distribution Agreement with Shanghai Universal Biotech Company 2BioAtom Inc. To Present at BIOCOM Investor Conference 2008 2
(Date:10/14/2014)... Like discriminating thieves, prostate cancer tumors scavenge and hoard ... But such avarice may be a fatal weakness. ... to kill prostate cancer cells by delivering a trove ... the diseased cells brimming with the mineral, leaving non-cancer ... drugs already commercially available for other uses, could soon ...
(Date:10/14/2014)... (Oct. 14, 2014)—It,s been millions of years since ... team led by Ohio University scientists is breathing life ... airflow through dinosaur snouts. The research has important implications ... breathe but to enhance the sense of smell and ... animals," said Ohio University doctoral student Jason Bourke, lead ...
(Date:10/14/2014)... to produce enough food to feed the world in ... of the United Nations predicts that food production must ... a growing global population, and plants are one major ... Plants—grains, cereals, fruits, vegetables, and more—feed humans directly and ... into our knowledge of how plants work to develop ...
Breaking Biology News(10 mins):Prostate cancer's penchant for copper may be a fatal flaw 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 2Dinosaur breathing study shows that noses enhanced smelling and cooled brain 3Building a bridge from basic botany to applied agriculture 2Building a bridge from basic botany to applied agriculture 3
... a celebrity living on mineral water, the glassy-winged sharpshooter ... in California, which is feverishly working to prevent the ... a surprising study published in the June 6 issue ... at The Institute for Genomic Research (TIGR), the University ...
... here have discovered a new mechanism used by cells ?and ... proteins, including some involved in cancer. , The mechanism ... made by the cell. , The study by researchers ... James Cancer Hospital and Richard J. Solove Research Institute and ...
... two frog species feared extinct has made a new ... save amphibians from a deadly fungus decimating their populations ... the two Critically Endangered frogs ?the Santa Marta harlequin ... (Atelopus nahumae) ?for the first time in 14 years ...
Cached Biology News:Surprising symbiosis: Glassy-winged sharpshooter eats with friends 2Surprising symbiosis: Glassy-winged sharpshooter eats with friends 3Scientists discover new regulating mechanism in cells 2Scientists discover new regulating mechanism in cells 3Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 2Race to halt global amphibian crisis boosted by rediscovery of endangered Colombian frogs 3
... Platypus Contact Printing Kit contains choice ... with series of 100 / 200 micron ... or 200 um x 10 mm lines, ... 20, 40 or 60 nm and pitch ...
...
... 5 ml of DETACHaBEAD Mouse CD4, polyclonal ... T cells from Dynabeads Mouse CD4 (L3T4). ... cells from Dynabeads Mouse CD4 using DETACHaBEAD ... for any downstream application including flow cytometry, ...
RECOMBINANT EQUINE IL-4 Product Type: Recombinant Protein...
Biology Products: